PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-19.90%
Both companies show declining cash positions (-19.90% vs CRVO's -12.35%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-19.90%
Cash + STI yoy ≥ 1.5x CRVO's -12.35%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.69%
≥ 1.5x CRVO's -11.65%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
6.10%
Below half CRVO's -3.39%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both CRVO and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.84%
Below half of CRVO's -2.20%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-18.44%
≥ 1.5x CRVO's -7.30%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
65.60%
Less than half of CRVO's -58.15%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
1.25-1.5x CRVO's -72.68%. Martin Whitman is cautious about near-term obligations overshadowing competitor's level.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both CRVO and the company show zero Deferred Revenue (Current) Growth.
-13.55%
Less than half of CRVO's 1.00%. David Dodd sees fewer expansions in other current obligations.
-8.01%
Less than half of CRVO's -27.94%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.01%
Less than half of CRVO's -16.07%. David Dodd sees far fewer liability expansions relative to competitor.
7.31%
Above 1.5x CRVO's 0.63%. Michael Burry suspects heavy new equity expansion or dilution.
-7.62%
1.25-1.5x CRVO's -5.17%. Bruce Berkowitz notes stronger reinvestment strategy.
-130.04%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-45.22%
≥ 1.5x CRVO's -5.51%. David Dodd sees stronger capital base growth than competitor.
-18.44%
≥ 1.5x CRVO's -7.30%. David Dodd sees faster overall balance sheet growth than competitor.
-100.00%
Both CRVO and the company show zero Total Investments Growth.
-100.00%
1.25-1.5x CRVO's -72.68%. Martin Whitman is wary of bigger debt expansions vs. competitor.
19.60%
Above 1.5x CRVO's 10.24%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.